| Autor: |
Carras, S., Torroja, A., Emadali, A., Daguindau, N., Tempescul, A., Macro, M., Moreau, A., Tchernonog, E., Houot, R., Schmitt, A., Dartigeas, C., Dupuis, J., Jardin, F., Banos, A., Corm, S., Barbieux, S., Zerazhi, H., Arkam, Y., Fouillet, L., Fontan, J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p481-483, 3p |
| Abstrakt: |
We also show that the presence of I TP53 i mutation and hypoalbuminemia (<36 g/L) are 2 independent PF for PFS and OS in elderly MCL patients included in the cohort. B Introduction: b Alterations in I TP53 i are a well known negative factor in young mantle cell lymphoma (MCL) patients eligible for intensive therapies, but their impact in elderly subjects remains poorly characterized. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text